Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and…

MWC 2025: Top 10 Innovative Highlights from FiberHome

BARCELONA, Spain, Feb. 28, 2025 /PRNewswire/ — Under the visionary theme "Connecting the Bright…

LubTop2024 and ApexTire2024: The 'Oscars' of the Automotive Aftermarket Unite to Chart a New Path

SHENZHEN, China, Feb. 28, 2025 /PRNewswire/ — In an era of rapid…

LILYSILK Opens First-Ever Concept Store in New York, Expanding Its Global Footprint with a Stunning Retail Experience

NEW YORK, Feb. 28, 2025 /PRNewswire/ — LILYSILK, the world’s leading silk…

SEMI Cybersecurity Consortium's NIST Semiconductor Manufacturing Community Profile Opens for Public Feedback

MILPITAS, Calif., Feb. 28, 2025 /PRNewswire/ — The SEMI Semiconductor Manufacturing Cybersecurity Consortium…

MinIO Grows ARR by 149% as Demand for AI Data Storage Skyrockets

Solidifies position as object storage of choice for AI amidst the rise…

Bybit Unveils USDT Flash Deal: Earn 15% APR and Share in a 300,000 USDT Prize Pool

DUBAI, UAE, Feb. 28, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange…

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE + RARE DISEASE DAY AWARENESS

NEW YORK, Feb. 28, 2025 /PRNewswire/ — The New York Stock Exchange…